New study seeks to identify who benefits from Last-Resort blood pressure drugs
NCT ID NCT07579260
First seen Jun 24, 2026 · Last updated Jun 30, 2026 · Updated 3 times
Summary
This study will follow 100 adults whose high blood pressure remains high despite taking at least two medications. Over three months, researchers will track changes in blood pressure and other health markers to find patterns that could help identify which patients might respond best to fourth-line treatments, including the FDA-approved drug aprocitentan. No new treatments are given; the goal is to gather real-world data to guide future care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help doctors identify which patients with resistant hypertension are most likely to benefit from newer medications like aprocitentan.
What could go wrong
This is an observational study, not a treatment trial. It will not test whether any drug works, and results may not apply to all patients with hypertension.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University Hospital
Durham, North Carolina, 27710, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Stanford University Hypertension Center
Palo Alto, California, 94304, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••